These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37145566)

  • 1. Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Prospective Multicenter Registry.
    Stout TE; Regmi SK; Daneshmand S; Porten SP; Pohar KS; Konety BR
    Urol Pract; 2022 Jan; 9(1):94-100. PubMed ID: 37145566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
    Chappidi MR; Yang H; Meng MV; Bivalacqua TJ; Daneshmand S; Holzbeierlein JM; Kaimakliotis HZ; Konety B; Liao JC; Pohar K; Steinberg GD; Taylor JM; Tyson MD; Willard B; Lotan Y; Porten SP; Kates M
    J Urol; 2022 Mar; 207(3):534-540. PubMed ID: 34694916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
    Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
    Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
    Ladi-Seyedian SS; Ghoreifi A; Konety B; Pohar K; Holzbeierlein JM; Taylor J; Kates M; Willard B; Taylor JM; Liao JC; Kaimakliotis HZ; Porten SP; Steinberg GD; Tyson MD; Lotan Y; Daneshmand S; Blue Light Cystoscopy With Cysview Registry Group
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
    Shore ND; Gavaghan MB
    Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
    Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
    Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
    Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
    BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.
    Lapini A; Minervini A; Masala A; Schips L; Pycha A; Cindolo L; Giannella R; Martini T; Vittori G; Zani D; Bellomo F; Cosciani Cunico S
    Surg Endosc; 2012 Dec; 26(12):3634-41. PubMed ID: 22729704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
    Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
    Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions.
    Bazargani ST; Djaladat H; Schuckman AK; Hugen CM; Daneshmand S
    Videourology (New Rochelle); 2018; 32(2):. PubMed ID: 31976152
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
    Ahmadi H; Ladi-Seyedian SS; Konety B; Pohar K; Holzbeierlein JM; Kates M; Willard B; Taylor JM; Liao JC; Kaimakliotis HZ; Porten SP; Steinberg GD; Tyson MD; Lotan Y; Daneshmand S;
    BJU Int; 2022 Jul; 130(1):62-67. PubMed ID: 34637596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promises and challenges of fluorescence cystoscopy.
    Lotan Y
    Urol Oncol; 2015 Jun; 33(6):261-4. PubMed ID: 25937623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
    Das S; Gu L; Eve CT; Parrish J; De Hoedt AM; McKee C; Aronson W; Freedland SJ; Williams SB
    Clin Genitourin Cancer; 2023 Dec; 21(6):711.e1-711.e6. PubMed ID: 37198099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States.
    Lewicki P; Arenas-Gallo C; Qiu Y; Venkat S; Basourakos SP; Scherr D; Shoag JE
    Eur Urol Focus; 2022 Jul; 8(4):968-971. PubMed ID: 34711530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
    Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
    Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer.
    Lee JS; Lee SY; Kim WJ; Seo SI; Jeon SS; Lee HM; Choi HY; Jeong BC
    Korean J Urol; 2012 Dec; 53(12):821-5. PubMed ID: 23301124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
    Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
    Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
    Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
    Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.